ReviewInternational journal of nanomedicine2016
Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
Review in International journal of nanomedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 121 citations in OpenAlex.
- Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2026Review
- Nanodrugs for Subcutaneous Mycoses: Applications, Antifungal Performance, and Translational Perspectives.Microorganisms · 2026Review
- Advancing antifungal therapy: exploring targeted CFW-PEc-enhanced ethosomal formulations of amphotericin B against cryptococcal pneumonia.Microbiology spectrum · 2025Article
- Exploring the Healing Powers of Histatins: From Oral Health to Therapeutics.International journal of molecular sciences · 2025Review
- Regulation of Ergosterol Biosynthesis in Pathogenic Fungi: Opportunities for Therapeutic Development.Microorganisms · 2025Review
- Novel Strategies for Preventing Fungal Infections-Outline.Pathogens (Basel, Switzerland) · 2025Review
- An overview of the mechanistic approaches of antifungal nanomaterials.Frontiers in pharmacology · 2025Review
- Strategies, Challenges, and Prospects of Nanoparticles in Gynecological Malignancies.ACS omega · 2024Review
- QTc Interval Prolongation as an Adverse Event of Azole Antifungal Drugs: Case Report and Literature Review.Microorganisms · 2024Review
- Challenges and Opportunities Arising from Host-International journal of molecular sciences · 2024Review
- Aflatoxins in Peanut (ACS omega · 2024Review
- Antimicrobial peptide AMP-17 induces protection against systemic candidiasis and interacts synergistically with fluconazole againstFrontiers in microbiology · 2024Article
- Calcofluor White-Phosphatidylethanolamine Conjugate-Enhanced Ethosomal Delivery of Voriconazole for TargetingInternational journal of nanomedicine · 2024Article
- Micro- and nanoparticles as platforms for the treatment of fungal infections: present and future perspectives.Future microbiology · 2023Article
- Traversing the Cell Wall: The Chitinolytic Activity ofJournal of fungi (Basel, Switzerland) · 2023Article
- Inorganic Nanoparticles: Tools to Emphasize the Janus Face of Amphotericin B.Antibiotics (Basel, Switzerland) · 2023Review
- Emerging Polymer-Based Nanosystem Strategies in the Delivery of Antifungal Drugs.Pharmaceutics · 2023Review
- Artificial nanovesicles for dsRNA delivery in spray-induced gene silencing for crop protection.Plant biotechnology journal · 2023Article
- Bioengineered materials with selective antimicrobial toxicity in biomedicine.Military Medical Research · 2023Review
- Nanotechnology-Based Approaches for Voriconazole Delivery Applied to Invasive Fungal Infections.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive mycoses are a major problem for immunocompromised individuals and patients in intensive care units. Morbidity and mortality rates of these infections are high because of late diagnosis and delayed treatment. Moreover, the number of available antifungal agents is low, and there are problems with toxicity and resistance. Alternatives for treating invasive fungal infections are necessary. Nanostructured systems could be excellent carriers for antifungal drugs, reducing toxicity and targeting their action. The use of nanostructured systems for antifungal therapy began in the 1990s, with the appearance of lipid formulations of amphotericin B. This review encompasses different antifungal drug delivery systems, such as liposomes, carriers based on solid lipids and nanostructure lipids, polymeric nanoparticles, dendrimers, and others. All these delivery systems have advantages and disadvantages. Main advantages are the improvement in the antifungal properties, such as bioavailability, reduction in toxicity, and target tissue, which facilitates innovative therapeutic techniques. Conversely, a major disadvantage is the high cost of production. In the near future, the use of nanosystems for drug delivery strategies can be used for delivering peptides, including mucoadhesive systems for the treatment of oral and vaginal candidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.